Request submitted by STADA to EMA to convert conditional marketing authorization to standard marketing authorization for Kinpeygo treatment for primary IgA nephropathy Submission to the CHMP for full approval is based on the full two-year data set from the Phase 3 NefIgArd clinical trial,…